Clinical trials show targeted kinase inhibitors provide high response rates in children with refractory histiocytic disorders ...
Sunvozertinib lung cancer treatment hit a milestone as AstraZeneca paid $600M upfront for Zegfrovy, the first oral pill to ...
Ananda Pharma Limited is a UK-based biopharmaceutical company developing regulatory approved cannabidiol medicines to treat complex, chronic conditions. It has lead programmes in endometriosis and ...
A Florida man with blood cancer couldn't afford his medication because of a little-known insurance policy called a co-pay ...
Children's hospitals manage drug shortages by addressing unique pediatric needs and operational challenges to ensure safe, effective care.
AstraZeneca pays $600M for global rights to Dizal’s lung cancer drug Zegfrovy, boosting its oncology pipeline.
SHANGHAI, July 14 (Reuters) - AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to one of its ...
Morning Overview on MSN
A drug hit its goal against an aggressive lymphoma in a late-stage trial
Patients with relapsed or refractory diffuse large B-cell lymphoma, one of the fastest-growing blood cancers, gained a new ...
Nearly a decade after spinning out its Chinese research hub to form Dizal Pharmaceutical, AstraZeneca is paying up to $1.5 billion to buy a piece of the pipeline, securing exclusive global rights for ...
Learn about notable updates that occurred in June 2026 for investigational products in development (not an inclusive list).
Mesothelioma is a rare but aggressive cancer, usually caused by exposure to asbestos. Inhaled asbestos fibers become lodged ...
AstraZeneca has acquired exclusive global rights to develop and commercialize Dizal Pharmaceutical’s marketed lung cancer drug Zegfrovy® (sunvozertinib), through an agreement that could generate up to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results